SS Innovations International (NASDAQ: SSII) Demonstrates Long-Distance Robotic Cardiac Surgery at Industry Events

Austin, Texas, United States, November 2nd, 2026, NewsDirect

• The company demonstrated its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console at two international medical conferences in October 2026.
• At the European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, CEO Dr. Sudhir Srivastava performed a robotic-assisted atrial septal defect procedure on a patient approximately 7,500 miles away in Bengaluru, India.
• Four additional robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric and gynecological procedures.
• The company reported 205 telesurgeries performed with the SSi Mantra system as of October 23, 2026, including cardiac procedures.
• The demonstrations highlight the potential for remote robotic surgery to extend specialist expertise beyond major medical centers, although widespread adoption depends on clinical validation, connectivity and regulatory requirements.
• SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027; the timeline remains subject to the FDA’s review.

SS Innovations (NASDAQ: SSII), a developer of innovative surgical robotic technologies, showcased its surgical robotics platform in a series of remote operations during October medical conferences in Spain and India, including a robotic-assisted cardiac procedure performed by a surgeon approximately 7,500 miles from the patient (https://ibn.fm/EZFDT).

The demonstrations featured the company’s SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console. At the 40th European Association for Cardio-Thoracic Surgery (“EACTS”) annual meeting in Barcelona, SS Innovations Chairman and Chief Executive Officer Dr. Sudhir Srivastava remotely performed an atrial septal defect procedure on a patient at…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]